title: Clinical decision making based on radionuclide determined ejection fraction in oncology patients.
abstract: Decreased left ventricular ejection fraction (LVEF) is a relative contraindication for the use of potentially cardiotoxic chemotherapy. A resting LVEF of 50% is usually used as the lower limit of normal values. The decision to change chemotherapy, however, is complex and is affected by many factors, including ejection fraction.
  
  
  METHODS
  To determine how LVEF data were used by clinical oncologists in clinical decision making, we performed a retrospective analysis of patients referred for ejection fraction measurements from the hematology/oncology divisionS of Stanford University from March 1992 through March 1995. The records of 565 patients treated with potentially cardiotoxic chemotherapy were evaluated.
  
  
  RESULTS
  LVEFs < 50% were found in 153 patients. The charts of patients with reduced ejection fractions were reviewed to determine if the radionuclide measurement resulted in either discontinuation of the cardiotoxic agent or substitution of a less cardiotoxic drug or mode of administration. These specific changes in therapy occurred in only 43 of the 153 (28%) patients with ejection fractions below 50%; 24 of the 43 (57%) had ejection fractions < or = 40%. Patients with lower ejection fraction values were more likely to have their therapy changed than those with LVEFs close to normal. Patients with ejection fractions < or = 30 generally had cardiotoxic agents discontinued. Of patients who had a resting LVEF < 50% and whose therapy was not changed, 81% had a normal increase in LVEF with exercise.
  
  
  CONCLUSIONS
  In clinical practice at our institution, ejection fraction < 50% is not used as an absolute contraindication to cardiotoxic chemotherapy. When the LVEF is less than 40%, potentially cardiotoxic therapy is most often discontinued or omitted. Radionuclide evidence of cardiac reserve may account for decisions to continue cardiotoxic agents despite ejection fractions < 50% in the majority of patients. Further study will be needed to establish standard criteria. Reserve function, as measured by the change in ejection fraction from rest to stress may be an important parameter used by oncologists to help select patients for continued therapy in spite of a reduced ejection fraction. Our results argue that use of fixed criteria may be too restrictive.
authors.affiliation: Department of Nuclear Medicine, Kaohsiung Veterans General Hospital, Taiwan.
authors.forename: N J
authors.initials: NJ
authors.lastname: Peng
authors.forename: R
authors.initials: R
authors.lastname: Advani
authors.forename: S
authors.initials: S
authors.lastname: Kopiwoda
authors.forename: G
authors.initials: G
authors.lastname: Fisher
authors.forename: H W
authors.initials: HW
authors.lastname: Strauss
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000075202:Contraindications; D003657:Decision Making; D004912:Erythrocytes; D005080:Exercise Test; D005260:Female; D015637:Gated Blood-Pool Imaging; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D013318:Stroke Volume; D013668:Technetium Tc 99m Aggregated Albumin; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging*
chemical_list: D000970:Antineoplastic Agents; D013668:Technetium Tc 99m Aggregated Albumin